About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(tetO/CMV-Tslp)#Sfz
transgene insertion, Steven F Ziegler
MGI:5317863
Summary 4 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cx1
Tg(KRT5-rtTA)1Glk/0
Tg(tetO/CMV-Tslp)#Sfz/0
C.Cg-Tg(KRT5-rtTA)1Glk Tg(tetO/CMV-Tslp)#Sfz MGI:5317912
cx2
Tcrbtm1Mom/Tcrbtm1Mom
Tg(KRT5-rtTA)1Glk/0
Tg(tetO/CMV-Tslp)#Sfz/0
involves: 129P2/OlaHsd * C3H * C57BL/6 * FVB/N MGI:5317870
cx3
Tg(KRT5-rtTA)1Glk/0
Tg(tetO/CMV-Tslp)#Sfz/0
involves: C3H * C57BL/6 * FVB/N MGI:5317865
cx4
Tg(KRT5-rtTA)1Glk/0
Tg(tetO-Tfrc/EGFP/Ova)#Sfz/0
Tg(tetO/CMV-Tslp)#Sfz/0
involves: C3H * C57BL/6 * FVB/N MGI:5503059


Genotype
MGI:5317912
cx1
Allelic
Composition
Tg(KRT5-rtTA)1Glk/0
Tg(tetO/CMV-Tslp)#Sfz/0
Genetic
Background
C.Cg-Tg(KRT5-rtTA)1Glk Tg(tetO/CMV-Tslp)#Sfz
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• dox treated mutants develop autoimmune hemolytic anemia (J:182756)
• dox treated mutants develop autoimmune hemolytic anemia (J:182756)
• mature follicular B cells in doxycycline (dox) treated mutants display features of polyclonal activation, including down-regulation of CD21/CD35 expression, elevated CD23 and MHC class II expression, increased cell size and increased mitogenic responses (J:182756)
• mature follicular B cells in doxycycline (dox) treated mutants display features of polyclonal activation, including down-regulation of CD21/CD35 expression, elevated CD23 and MHC class II expression, increased cell size and increased mitogenic responses (J:182756)
• following polyclonal stimulation in vitro, primary B cells from dox treated mutants exhibit higher levels of [3H] thymidine incorporation, indicating increased proliferation potential (J:182756)
• following anti-IgM and LPS stimulation, primary B cells from dox treated mutants, exhibit higher levels of BrdU incorporation, indicating increased proliferation potential (J:182756)
• following polyclonal stimulation in vitro, primary B cells from dox treated mutants exhibit higher levels of [3H] thymidine incorporation, indicating increased proliferation potential (J:182756)
• following anti-IgM and LPS stimulation, primary B cells from dox treated mutants, exhibit higher levels of BrdU incorporation, indicating increased proliferation potential (J:182756)
• dox treated mutants exhibit an increase in serum IL-4 levels (J:182756)
• dox treated mutants exhibit an increase in serum IL-4 levels (J:182756)
• following dox treatment, mutants show the presence of anti-RBC-specific autoantibodies (J:182756)
• following dox treatment, mutants show the presence of anti-RBC-specific autoantibodies (J:182756)

hematopoietic system
• dox treated mutants develop autoimmune hemolytic anemia (J:182756)
• dox treated mutants develop autoimmune hemolytic anemia (J:182756)
• following dox treatment, mutants show a decrease in hematocrit corresponding with the presence of anti-RBC-specific autoantibodies, consistent with onset of hemolytic anemia (J:182756)
• following dox treatment, mutants show a decrease in hematocrit corresponding with the presence of anti-RBC-specific autoantibodies, consistent with onset of hemolytic anemia (J:182756)
• mature follicular B cells in doxycycline (dox) treated mutants display features of polyclonal activation, including down-regulation of CD21/CD35 expression, elevated CD23 and MHC class II expression, increased cell size and increased mitogenic responses (J:182756)
• mature follicular B cells in doxycycline (dox) treated mutants display features of polyclonal activation, including down-regulation of CD21/CD35 expression, elevated CD23 and MHC class II expression, increased cell size and increased mitogenic responses (J:182756)
• following polyclonal stimulation in vitro, primary B cells from dox treated mutants exhibit higher levels of [3H] thymidine incorporation, indicating increased proliferation potential (J:182756)
• following anti-IgM and LPS stimulation, primary B cells from dox treated mutants, exhibit higher levels of BrdU incorporation, indicating increased proliferation potential (J:182756)
• following polyclonal stimulation in vitro, primary B cells from dox treated mutants exhibit higher levels of [3H] thymidine incorporation, indicating increased proliferation potential (J:182756)
• following anti-IgM and LPS stimulation, primary B cells from dox treated mutants, exhibit higher levels of BrdU incorporation, indicating increased proliferation potential (J:182756)

homeostasis/metabolism
• dox treated mutants exhibit an increase in serum IL-4 levels (J:182756)
• dox treated mutants exhibit an increase in serum IL-4 levels (J:182756)

Mouse Models of Human Disease
OMIM ID Ref(s)
Anemia, Autoimmune Hemolytic 205700 J:182756




Genotype
MGI:5317870
cx2
Allelic
Composition
Tcrbtm1Mom/Tcrbtm1Mom
Tg(KRT5-rtTA)1Glk/0
Tg(tetO/CMV-Tslp)#Sfz/0
Genetic
Background
involves: 129P2/OlaHsd * C3H * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tcrbtm1Mom mutation (12 available); any Tcrb mutation (77 available)
Tg(KRT5-rtTA)1Glk mutation (0 available)
Tg(tetO/CMV-Tslp)#Sfz mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
integument
• mutants treated with dox for 3 weeks exhibit dermal infiltration mostly of mast cells and eosinophils (J:100506)
• mutants treated with dox for 3 weeks exhibit dermal infiltration mostly of mast cells and eosinophils (J:100506)
• mutants treated with doxycycline (dox) for 3 weeks exhibit dermal infiltration mostly of mast cells and eosinophils (J:100506)
• mutants treated with doxycycline (dox) for 3 weeks exhibit dermal infiltration mostly of mast cells and eosinophils (J:100506)
• mutants treated with dox for 3 weeks exhibit epidermal thickening (J:100506)
• mutants treated with dox for 3 weeks exhibit epidermal thickening (J:100506)

immune system
• dox treated mice exhibit little or no serum IgE (J:100506)
• dox treated mice exhibit little or no serum IgE (J:100506)
• mutants treated with dox for 3 weeks exhibit dermal infiltration mostly of mast cells and eosinophils (J:100506)
• mutants treated with dox for 3 weeks exhibit dermal infiltration mostly of mast cells and eosinophils (J:100506)

hematopoietic system
• dox treated mice exhibit little or no serum IgE (J:100506)
• dox treated mice exhibit little or no serum IgE (J:100506)




Genotype
MGI:5317865
cx3
Allelic
Composition
Tg(KRT5-rtTA)1Glk/0
Tg(tetO/CMV-Tslp)#Sfz/0
Genetic
Background
involves: C3H * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
integument
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis (J:100506)
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis (J:100506)
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment (J:100506)
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils (J:100506)
• however, inflammation is not seen in the small intestine or colon (J:100506)
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment (J:100506)
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils (J:100506)
• however, inflammation is not seen in the small intestine or colon (J:100506)
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including hyperkeratosis (J:100506)
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including hyperkeratosis (J:100506)
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including acanthosis (J:100506)
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including acanthosis (J:100506)
• majority of dox treated mice exhibit a mild xerosis (J:100506)
• majority of dox treated mice exhibit a mild xerosis (J:100506)
• seen in dox treated mutants (J:100506)
• seen in dox treated mutants (J:100506)
• dox treated mutants exhibit skin lesions consisting of mild erythema at 2 weeks of dox treatment with progression to eczematous-like changes, including erythema, crusting, and erosions, by 3-4 weeks of dox treatment (J:100506)
• skin lesions are most common on the snout, postauricular region, nape of the neck and upper back (J:100506)
• less commonly, lesions are seen on the anterior neck and hind legs (J:100506)
• dox treated mutants exhibit skin lesions consisting of mild erythema at 2 weeks of dox treatment with progression to eczematous-like changes, including erythema, crusting, and erosions, by 3-4 weeks of dox treatment (J:100506)
• skin lesions are most common on the snout, postauricular region, nape of the neck and upper back (J:100506)
• less commonly, lesions are seen on the anterior neck and hind legs (J:100506)

immune system
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes (J:100506)
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes (J:100506)
• dox treated mutants exhibit splenomegaly (J:100506)
• dox treated mutants exhibit splenomegaly (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin (J:100506)
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin (J:100506)
• dox treated mutants exhibit a 14-fold increase in IL-4 producing cells in the skin-draining lymph nodes and an 18-fold increase in the intestinal mesenteric lymph nodes (J:100506)
• dox treated mutants exhibit a 14-fold increase in IL-4 producing cells in the skin-draining lymph nodes and an 18-fold increase in the intestinal mesenteric lymph nodes (J:100506)
• dox treated mutants exhibit lymphadenopathy (J:100506)
• dox treated mutants exhibit lymphadenopathy (J:100506)
• a few dox treated mice exhibit conjunctivitis (J:100506)
• a few dox treated mice exhibit conjunctivitis (J:100506)
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment (J:100506)
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils (J:100506)
• however, inflammation is not seen in the small intestine or colon (J:100506)
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment (J:100506)
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils (J:100506)
• however, inflammation is not seen in the small intestine or colon (J:100506)

hematopoietic system
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes (J:100506)
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes (J:100506)
• dox treated mutants exhibit splenomegaly (J:100506)
• dox treated mutants exhibit splenomegaly (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)

homeostasis/metabolism
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis (J:100506)
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis (J:100506)
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin (J:100506)
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin (J:100506)

vision/eye
• a few dox treated mice exhibit conjunctivitis (J:100506)
• a few dox treated mice exhibit conjunctivitis (J:100506)

Mouse Models of Human Disease
OMIM ID Ref(s)
Dermatitis, Atopic 603165 J:100506




Genotype
MGI:5503059
cx4
Allelic
Composition
Tg(KRT5-rtTA)1Glk/0
Tg(tetO-Tfrc/EGFP/Ova)#Sfz/0
Tg(tetO/CMV-Tslp)#Sfz/0
Genetic
Background
involves: C3H * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• of ovalbumin-specific CD4 T cells in doxycycline-treated mice unlike when cells are transferred into control mice (J:199558)
• of ovalbumin-specific CD4 T cells in doxycycline-treated mice unlike when cells are transferred into control mice (J:199558)
• airway inflammation in doxycycline-treated mice treated intranasally with ovalbumin (J:199558)
• airway inflammation in doxycycline-treated mice treated intranasally with ovalbumin (J:199558)
• eczematous inflammation in the skin of doxycycline- and anti-mTSLP antibody-treated mice (J:199558)
• eczematous inflammation in the skin of doxycycline- and anti-mTSLP antibody-treated mice (J:199558)

integument
• eczematous inflammation in the skin of doxycycline- and anti-mTSLP antibody-treated mice (J:199558)
• eczematous inflammation in the skin of doxycycline- and anti-mTSLP antibody-treated mice (J:199558)

respiratory system
• airway inflammation in doxycycline-treated mice treated intranasally with ovalbumin (J:199558)
• airway inflammation in doxycycline-treated mice treated intranasally with ovalbumin (J:199558)

hematopoietic system
• of ovalbumin-specific CD4 T cells in doxycycline-treated mice unlike when cells are transferred into control mice (J:199558)
• of ovalbumin-specific CD4 T cells in doxycycline-treated mice unlike when cells are transferred into control mice (J:199558)





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory